IBD
Inspire Corporate Bond ETF
Set alert
23.23 USD +0.08 +0.35%
23.20 Day range 23.36
23.00 52-week range 24.35
- YTD
- -4.01%
- 1 year
- -3.49%
- Open
- 23.22
- Prev close
- 23.15
- Mkt cap
- 481.43M
- Vol
- 110.51K
- Avg vol
- 101.23K
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 23.20
- High
- 23.36
- Forward P/E
- 0.00
- Beta
- 0.00
- Short ratio
- 0.00
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 23.72
- 200-d avg
- 23.63
Key statistics
- Market cap
- 0
- Enterprise value
- 0
- Trailing P/E
- 0.00
- Forward P/E
- 0.00
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- EPS (TTM)
- 0.00
- Beta
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Shares outstanding
- 0
- Short % of float
- 0.00%
- 50-day average
- 23.72
- 200-day average
- 23.63
About Inspire Corporate Bond ETF
The fund generally invests at least 80% of its total assets in the component securities of the index. The index Provider selects domestic corporate bonds issued by companies that are considered large capitalization companies, are rated investment grade quality from a bond ratings agency widely recognized in the financial services industry and which have an Inspire Impact Score of zero or higher.
News
- How Did This Low-Growth Stock Sneak Into IBD Growth Screens?
- Meta's $1,000 Bull Case: How Muse AI Changes The Valuation Game | IBD
- SKYRIZI® (risankizumab) and RINVOQ® (upadacitinib) Data Highlight Long-Term Clinical and Endoscopic Outcomes Across Inflammatory Bowel Disease (IBD) at UEGW 2026
- SKYRIZI® (risankizumab) and RINVOQ® (upadacitinib) Data Highlight Long-Term Clinical and Endoscopic Outcomes Across Inflammatory Bowel Disease (IBD) at UEGW 2026
- Is Inspire Corporate Bond ETF (IBD) a Strong ETF Right Now?
- Celltrion to Present New Analyses of ZYMFENTRA® (infliximab-dyyb) in Crohn's Disease and Ulcerative Colitis at ACG 2026
- New SKYRIZI® (risankizumab-rzaa) and RINVOQ® (upadacitinib) Data Demonstrate Disease Control for Patients Living With Inflammatory Bowel Disease
- New Opportunities for Global Cooperation: Kexing Biopharm Shines at CPHI Milan 2026
- Spyre: Maintain 'Strong Buy' On Additional SPY072 Shots On Goal Q4 2026 And IBD Combination Potential
- AI-Fueled Precision Oncology Firm Guardant Health Is In Focus. Here's Why.
Your note
Sign in to keep a note on IBD — it syncs with the Stock Master app.